1. O-136 Once-daily relugolix combination therapy results in sustained reduction in symptoms and improved quality of life in women with uterine fibroids treated over 52 weeks. (6th August 2021) Authors: Lukes, A; Venturella, R; Al-Hendy, A; Nyirady, T; Decleer, W; Petraglia, F; Li, Y; Wagman, R B; Hunsche, E; Stewart, E A Journal: Human reproduction Issue: Volume 36:Supplement 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P-315 The importance of treatment features beyond pain reduction associated with gonadotropin-releasing hormone analogues from the patient perspective. (30th June 2022) Authors: Maculaitis, M; Hunsche, E; Cislo, P; Ansani, N; Virro, J; Will, O; Peck, E; Kopenhafer, L; Olsen, P; Hauber, A; Beusterien, K; Kim, R Journal: Human reproduction Issue: Volume 37(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗